Rimonabant and type 2 diabetes: results of the RIO study
Rimonabant is a cannabinoid receptor antagonist that has been licensed as an antiobesity drug. While more long-term studies are needed before definitive recommendations can be made for its use, it has been thought that it might have a role in obese or overweight people with type 2 diabetes. The RIO-Diabetes study aimed to assess just that.
Peter Burrill BPharm(Hons), MRPharmS DipPresSci FCPP FFPMM
Specialist Pharmaceutical Adviser for Public Health